Manages manifestations of psychotic disorders. ANDA 218173, held by Alembic. Fluphenazine Hydrochloride.
As of Nov 19, 2026, ANDA 218173 (Fluphenazine Hydrochloride), held by Alembic, was first approved by FDA on Jul 23, 2024, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Fluphenazine hydrochloride tablets are indicated in the management of manifestations of psychotic disorders. Fluphenazine hydrochloride has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 23, 2024 | Original application | Approved | None posted |
| Fluphenazine Hydrochloride1MG · tablet;oral | Fluphenazine Hydrochloride | Rx |
| Fluphenazine Hydrochloride2.5MG · tablet;oral | Fluphenazine Hydrochloride | Rx |
| Fluphenazine Hydrochloride5MG · tablet;oral | Fluphenazine Hydrochloride | Rx |
| Fluphenazine Hydrochloride10MG · tablet;oral | Fluphenazine Hydrochloride | Rx |
| Jan 22, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 23, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters